[3-(methoxymethoxy)phenyl]methanamine | 553611-73-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [3-(methoxymethoxy)phenyl]methanamine
• 英文别名: 1-[3-(Methoxymethoxy)phenyl]methanamine
• CAS: 553611-73-7
• 化学式: C₉H₁₃NO₂
• 分子量: 167.208
• InChiKey: VBZKHDJMECGSER-UHFFFAOYSA-N

物化性质

• 沸点：
  276.1±25.0 °C(Predicted)
• 密度：
  1.069±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  44.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  [3-(methoxymethoxy)phenyl]methanamine 在 哌啶 、 盐酸 、 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 72.0h， 生成 8-hydroxy-2-imino-2H-chromene-3-carboxylic acid 3-hydroxybenzylamide
  参考文献：
  名称：

  Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1

  摘要：

  人类酮醛还原酶1（CBR1）是短链脱氢酶/还原酶超家族的成员，它将蒽环类抗癌药物还原为它们较不具有抗癌作用的C-13羟基代谢物，这些代谢物与心脏毒性的发病机制有关，这是药物的副作用。

  DOI：

  10.1039/c5ob00847f

文献信息

• HETEROCYCLIC COMPOUND HAVING ANTI-HIV ACTIVITY
  申请人：Toyama Chemical Co., Ltd.

  公开号：EP2810944A1

  公开（公告）日：2014-12-10

  A heterocyclic compound represented by the general formula (in the formula, R1, R2 and R3 may be the same or different, and each represents a hydrogen atom, a halogen atom, or this general formula (X1-Y1-R4) (in the formula: X1 represents this general formula (NR5) (in the formula, R5 represents a hydrogen atom, etc.) or the like; Y1 represents an optionally substituted C1-6 alkylene group or the like; and R4 represents an optionally substituted aryl group or the like), and Z represents a nitrogen atom or this general formula (CR6) (in the formula, R6 represents a hydrogen atom, a halogen atom, or an optionally substituted C1-12 alkyl group or the like)), or a salt thereof, exhibits excellent anti-HIV activity and is useful as an anti-HIV agent.

  由一般公式表示的杂环化合物（在公式中，R1、R2和R3可以相同也可以不同，每个表示氢原子、卤原子或这一般式（X1-Y1-R4）（在公式中：X1表示这一般式（NR5）（在公式中，R5表示氢原子等）或类似物；Y1表示可选择地取代的C1-6烷基链或类似物；R4表示可选择地取代的芳基或类似物），Z表示氮原子或这一般式（CR6）（在公式中，R6表示氢原子、卤原子或可选择地取代的C1-12烷基链或类似物）），或其盐，表现出优异的抗HIV活性，并可用作抗HIV剂。
• Urea derivatives
  申请人：Yura Takeshi

  公开号：US20050154230A1

  公开（公告）日：2005-07-14

  This invention relates to urea derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The urea derivatives of the present invention has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.

  这项发明涉及脲衍生物及其盐，可用作制药制剂的活性成分。本发明的脲衍生物具有出色的VR1拮抗剂活性，可用于预防和治疗与VR1活性相关的疾病，特别是用于治疗急迫性尿失禁、过度活动膀胱、慢性疼痛、神经痛、术后疼痛、类风湿关节痛、神经痛、神经病、疼痛、神经损伤、缺血、神经退行性疾病、中风、失禁和/或炎症性疾病的治疗。
• UREA DERIVATIVES AS VR1-ANTAGONISTS
  申请人：Bayer HealthCare AG

  公开号：EP1461311A2

  公开（公告）日：2004-09-29
• [EN] UREA DERIVATIVES AS VR1- ANTAGONISTS<br/>[FR] DERIVES D'UREE
  申请人：BAYER AG

  公开号：WO2003055848A2

  公开（公告）日：2003-07-10

  This invention relates to urea derivatives of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof: (I) wherein Y is R1- R6 and X have the same meanings given in the description, which is useful as an active ingredient of pharmaceutical preparations. The urea derivatives of the present invention has an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and/or inflammatory disorders.
• Synthesis of 8-hydroxy-2-iminochromene derivatives as selective and potent inhibitors of human carbonyl reductase 1
  作者：Dawei Hu、Namiki Miyagi、Yuki Arai、Hiroaki Oguri、Takeshi Miura、Toru Nishinaka、Tomoyuki Terada、Hiroaki Gouda、Ossama El-Kabbani、Shuang Xia、Naoki Toyooka、Akira Hara、Toshiyuki Matsunaga、Akira Ikari、Satoshi Endo

  DOI：10.1039/c5ob00847f

  日期：——

  Human carbonyl reductase 1 (CBR1), a member of the short-chain dehydrogenase/reductase superfamily, reduces anthracycline anticancer drugs to their less potent anticancer C-13 hydroxy metabolites, which are linked with pathogenesis of cardiotoxicity, a side effect of the drugs.

  人类羰基还原酶1（CBR1）是短链脱氢酶/还原酶超家族的成员，它将蒽环类抗癌药物还原为它们的较不具有抗癌作用的C-13羟基代谢物，这些代谢物与心脏毒性的发病机制相关，是这些药物的副作用之一。